YD Bio Limited (YDES)

Nasdaq: YDES · Services-Medical Laboratories · Irving, TX · filing with the SEC since 2024

Full chart Alerts Compare

Grade5.6

◀ Past 7.6● Present 3.6▶ Future 6.3

3 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of YD Bio Limited

Nine metrics read from its own filings, by tense

Headline grade

5.6/10

◀ Past7.630% of the headline

● Present3.640% of the headline

▶ Future6.330% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 6 read as filed from the record and 3 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

7.6/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

7.8/10

Has it survived what it has been through?

No warning events in its filings since 2024.

weight 33% of this tense · 78th percentile among 27 sector filers · read for itself

From the record

YD Bio Limited's filings since 2024 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

7.4/10

What has it actually done, year after year?

+30.5% a year over 3 filed years; profitable in 1 of 3.

weight 45% of this tense · 74th percentile among 23 sector filers · read for its customers

From the record

YD Bio Limited's 3 filed years say what it did: revenue went from $350 thousand in fiscal 2023 to $597 thousand in fiscal 2025, up 30.5% a year; it rose in 2 of 2 years; it never fell from a peak; net income was positive in 1 of 3 of those years (its annual reports).

What it rests on

revenue growth over the filed span30.5%top 41% of its family
the share of years revenue rosetop 15% of its family
the share of filed years with a profittop 33% of its family
the deepest fall from a revenue peak0.0%top 15% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

8.0/10

How has it treated the people who own it?

SI estimate 8.0/10, confidence 35 of 100 (one part).

weight 22% of this tense · 80th percentile among 24 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the top 20% of 24 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 24 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: YD Bio Limited's shareholder treatment is put at 8.0 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 20% of 24 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

3.6/1040% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

2.8/10

Is it financially healthy right now?

Leverage 121%: owes 121¢ per asset dollar.

weight 33% of this tense · 28th percentile among 25 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, YD Bio Limited's shareholders' equity was below zero, so the profit on it is not read, and gross profitability: its products earned about 1 cents per dollar of everything the company owns. Leverage: it owed about 121 cents per dollar of assets, and net share issuance: its share count grew 3.1% over the year (the filed statements).

What it rests on

what it owes per dollar of assetsbottom 2% of its family
gross profit against assetsbottom 22% of its family
the share count against the year beforetop 39% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

3.1/10

How strong is its position in its industry?

bottom 31% of 24 in its family; net margin -1392.6%.

weight 45% of this tense · 31st percentile among 24 sector filers · read for its customers

From the record

YD Bio Limited's standing among 24 graded names in its industry family: revenue of $597 thousand in fiscal 2025 ranks in the bottom 15% by size; a net margin of -1392.6% ranks in the bottom 10%; revenue growth of 30.5% a year over the last 2 filed years ranks in the top 33% (its annual reports).

What it rests on

revenue against the family$596,817bottom 15% of its family
net margin-1392.6%bottom 10% of its family
three-year revenue growth30.5%top 33% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

5.9/10

What are the people in charge doing?

SI estimate 5.9/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 20 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 20 members with one.
What the record cannot read: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge.
How it was reasoned: family median, 20 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: YD Bio Limited's leadership is put at 5.9 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 20 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

6.3/1030% of the headline grade · 2 of 3 filed, 1 estimated

Room to expand

as filed

5.6/10

How much room does it have to grow?

top 44% of 24 in its family for room to expand.

weight 22% of this tense · 56th percentile among 24 sector filers · read for itself

From the record

YD Bio Limited's room to grow, from the newest filed statements (fiscal 2025): cash of $6 million against debt of $7 thousand leaves 43.5% of its assets as net cash, top 17% of its family; cash from operations less capital spending is -1346.6% of revenue (bottom 15%); a gross margin of 28.1% (bottom 41%); research spending of 268.4% of revenue (top 14%) (its annual report).

What it rests on

cash less debt against assets43.5%top 17% of its family
cash from operations less capital spending against revenue-1346.6%bottom 15% of its family
gross margin28.1%bottom 41% of its family
research spending against revenue268.4%top 14% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

7.8/10

What could actually drive growth from here?

top 22% of 23 in its family for growth drivers.

weight 45% of this tense · 78th percentile among 23 sector filers · read for its customers

From the record

YD Bio Limited's growth drivers, from the filed years to fiscal 2025: revenue grew 30.5% a year over the last three filed years against 30.5% over all 3, speeding up (top 43% of its family); the newest year grew 17% (top 41%); research spending grew 226.3% a year (top 3%); capital spending grew 6926.2% a year (top 2%) (its annual reports). YD Bio Limited reported 6 product lines in fiscal 2025: Medical and Related Products at $281 thousand (47%), Drugs at $223 thousand (37%), Beauty Products at $50 thousand (8%), and 3 more; 1 of 4 grew against the year before (its annual report).

What it rests on

three-year growth against the whole span+0.0 points a yeartop 43% of its family
the newest year's revenue growth17.0%top 41% of its family
three-year growth of research spending226.3%top 3% of its family
three-year growth of capital spending6926.2%top 2% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

SI estimate

4.7/10

Did its newest year beat what its own record pointed to?

SI estimate 4.7/10, confidence 20 of 100 (family median).

weight 33% of this tense · 50th percentile among 20 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 20 members with one.
What the record cannot read: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned: family median, 20 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: YD Bio Limited's expectations vs reality is put at 4.7 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 20 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton YDES · research, not advice